Skip to Main Content

629

Views

1

CrossRef citations to date

0

Altmetric

Oncology

Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective

Thor-Henrik Brodtkorba RTI Health Solutions, Ljungskile, Sweden

https://orcid.org/0000-0002-9899-233X View further author information

,

Christopher Knightb RTI Health Solutions, Manchester, UKView further author information

,

Farzam Kamgara RTI Health Solutions, Ljungskile, SwedenView further author information

,

Siguroli Teitssonc Bristol Myers Squibb, Uxbridge, UKCorrespondence[email protected]

https://orcid.org/0009-0001-7378-1675 View further author information

,

Murat Kurtd Bristol Myers Squibb, Princeton, NJ, USAView further author information

,

Miraj Y. Pateld Bristol Myers Squibb, Princeton, NJ, USA

https://orcid.org/0000-0002-3543-1420 View further author information

,

Tayla Porettad Bristol Myers Squibb, Princeton, NJ, USAView further author information

,

Ronac Mamtanie Division of Hematology - Oncology, University of Pennsylvania, Philadelphia, PA, USAView further author information

&

Stephen Palmerf Centre for Health Economics, University of York, York, UK

https://orcid.org/0000-0002-7268-2560 View further author information